Events

Date: Tuesday, November 7, 2023 Time: 2:00pm - 3:00pm ET TITLE: Case Studies of Using BeneFix® (Coagulation Factor IX ) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story? SPEAKER: Doris Quon, MD Medical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute Read the full article...

Date: Thursday, November 9, 2023 Time: 1:00pm - 2:00pm ET TITLE: Learn More About Subcutaneous Prophylaxis Treatment for Hemophilia A: A Discussion on the Latest Data and Patient Management DESCRIPTION: Please join us for an engaging webinar led by Ketna Mistry, MD who will be sharing information on patients with hemophilia A with a subcutaneous Read the full article...

Date: Monday, November 13, 2023 Time: 1:00pm - 2:00pm ET TITLE: Hemgenix Real World Learnings SPEAKER: Vidhi Desai, MD Senior Medical Director, Coagulation North America Medical Affairs Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Idelvion®, Read the full article...

Date: Friday, November 17, 2023 Time: 1:00pm - 2:00pm ET TOPIC: Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® OVERVIEW: This session includes key information about Jivi including, safety and efficacy data from the clinical trials, step-wise dosing and Jivi RWE Data from HEM-POWR, Read the full article...

Date: Monday, November 27, 2023 Time: 1:00pm - 2:00pm ET TITLE: A different treatment option for Inhibitor patients OBJECTIVE: This presentation will provide an overview of inhibitors and explore the efficacy, safety, tolerability, clinical development, and reasons to consider a different treatment option. TARGET AUDIENCE: All HTC Staff SPEAKER: Guy Young, MD. Director, Hemostasis and Read the full article...

Date: Wednesday, November 29, 2023 Time: 1:00pm - 2:00pm ET TITLE: Overview of Adzynma (rADAMTS13) Prescribing Information OBJECTIVE: Inform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP. TARGET AUDIENCE: Hematologists, NPs, nurses, pharmacists SPEAKER: Ali Mokdad, MD, PhD, MBA, Medical Director, Takeda